184 related articles for article (PubMed ID: 24853183)
1. Multi-colour FISH in oesophageal adenocarcinoma-predictors of prognosis independent of stage and grade.
Geppert CI; Rümmele P; Sarbia M; Langer R; Feith M; Morrison L; Pestova E; Schneider-Stock R; Hartmann A; Rau TT
Br J Cancer; 2014 Jun; 110(12):2985-95. PubMed ID: 24853183
[TBL] [Abstract][Full Text] [Related]
2. Fluorescence in situ hybridization identifies high risk Barrett's patients likely to develop esophageal adenocarcinoma.
Brankley SM; Halling KC; Jenkins SM; Timmer MR; Iyer PG; Smyrk TC; Barr Fritcher EG; Voss JS; Kipp BR; Campion MB; Lutzke LS; Minot DM; Wang KK
Dis Esophagus; 2016 Aug; 29(6):513-9. PubMed ID: 26043762
[TBL] [Abstract][Full Text] [Related]
3. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
[TBL] [Abstract][Full Text] [Related]
4. Fluorescence in situ hybridization mapping of esophagectomy specimens from patients with Barrett's esophagus with high-grade dysplasia or adenocarcinoma.
Brankley SM; Fritcher EG; Smyrk TC; Keeney ME; Campion MB; Voss JS; Clayton AC; Wang KK; Lutzke LS; Kipp BR; Halling KC
Hum Pathol; 2012 Feb; 43(2):172-9. PubMed ID: 21820152
[TBL] [Abstract][Full Text] [Related]
5. High-resolution genomic alterations in Barrett's metaplasia of patients who progress to esophageal dysplasia and adenocarcinoma.
Sepulveda JL; Komissarova EV; Kongkarnka S; Friedman RA; Davison JM; Levy B; Bryk D; Jobanputra V; Del Portillo A; Falk GW; Sonett JR; Lightdale CJ; Abrams JA; Wang TC; Sepulveda AR
Int J Cancer; 2019 Nov; 145(10):2754-2766. PubMed ID: 31001805
[TBL] [Abstract][Full Text] [Related]
6. A Multicenter Study of a Fluorescence In Situ Hybridization Probe Set for Diagnosing High-Grade Dysplasia and Adenocarcinoma in Barrett's Esophagus.
Poneros JM; Faye AS; Barr Fritcher EG; Sen A; Anandasabapathy S; Bresalier RS; Marcon N; Turgeon DK; Appelman H; Normolle D; Morrison LE; Brenner DE; Halling KC
Dig Dis Sci; 2017 May; 62(5):1216-1222. PubMed ID: 28265829
[TBL] [Abstract][Full Text] [Related]
7. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
[TBL] [Abstract][Full Text] [Related]
8. HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients.
Dunne MR; Michielsen AJ; O'Sullivan KE; Cathcart MC; Feighery R; Doyle B; Watson JA; O'Farrell NJ; Ravi N; Kay E; Reynolds JV; Ryan EJ; O'Sullivan J
Cancer Immunol Immunother; 2017 Jul; 66(7):841-850. PubMed ID: 28315927
[TBL] [Abstract][Full Text] [Related]
9. Integrative analysis of array-comparative genomic hybridisation and matched gene expression profiling data reveals novel genes with prognostic significance in oesophageal adenocarcinoma.
Goh XY; Rees JR; Paterson AL; Chin SF; Marioni JC; Save V; O'Donovan M; Eijk PP; Alderson D; Ylstra B; Caldas C; Fitzgerald RC
Gut; 2011 Oct; 60(10):1317-26. PubMed ID: 21478220
[TBL] [Abstract][Full Text] [Related]
10. Aneusomy detected by fluorescence in-situ hybridization has high positive predictive value for Barrett's dysplasia.
Allan EA; Miller R; Going JJ
Histopathology; 2015 Oct; 67(4):451-6. PubMed ID: 25735914
[TBL] [Abstract][Full Text] [Related]
11. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas.
Yoon HH; Shi Q; Sukov WR; Wiktor AE; Khan M; Sattler CA; Grothey A; Wu TT; Diasio RB; Jenkins RB; Sinicrope FA
Clin Cancer Res; 2012 Jan; 18(2):546-54. PubMed ID: 22252257
[TBL] [Abstract][Full Text] [Related]
12. Array-based comparative genomic hybridization for the detection of DNA sequence copy number changes in Barrett's adenocarcinoma.
Albrecht B; Hausmann M; Zitzelsberger H; Stein H; Siewert JR; Hopt U; Langer R; Höfler H; Werner M; Walch A
J Pathol; 2004 Jul; 203(3):780-8. PubMed ID: 15221937
[TBL] [Abstract][Full Text] [Related]
13. Coamplification and coexpression of GRB7 and ERBB2 is found in high grade intraepithelial neoplasia and in invasive Barrett's carcinoma.
Walch A; Specht K; Braselmann H; Stein H; Siewert JR; Hopt U; Höfler H; Werner M
Int J Cancer; 2004 Dec; 112(5):747-53. PubMed ID: 15386389
[TBL] [Abstract][Full Text] [Related]
14. Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus.
Prasad GA; Wang KK; Halling KC; Buttar NS; Wongkeesong LM; Zinsmeister AR; Brankley SM; Fritcher EG; Westra WM; Krishnadath KK; Lutzke LS; Borkenhagen LS
Gastroenterology; 2008 Aug; 135(2):370-9. PubMed ID: 18538141
[TBL] [Abstract][Full Text] [Related]
15. High Expression of Cathepsin E in Tissues but Not Blood of Patients with Barrett's Esophagus and Adenocarcinoma.
Fisher OM; Levert-Mignon AJ; Lord SJ; Botelho NK; Freeman AK; Thomas ML; Falkenback D; Wettstein A; Whiteman DC; Bobryshev YV; Lord RV
Ann Surg Oncol; 2015 Jul; 22(7):2431-8. PubMed ID: 25348778
[TBL] [Abstract][Full Text] [Related]
16. Quantitative analysis of p16 methylation in Barrett's carcinogenesis.
Chueca E; Valero A; Hördnler C; Puertas A; Carrera P; García-González MA; Strunk M; Lanas A; Piazuelo E
Ann Diagn Pathol; 2020 Aug; 47():151554. PubMed ID: 32570024
[TBL] [Abstract][Full Text] [Related]
17. Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma.
Akagi T; Ito T; Kato M; Jin Z; Cheng Y; Kan T; Yamamoto G; Olaru A; Kawamata N; Boult J; Soukiasian HJ; Miller CW; Ogawa S; Meltzer SJ; Koeffler HP
Int J Cancer; 2009 Nov; 125(10):2349-59. PubMed ID: 19670330
[TBL] [Abstract][Full Text] [Related]
18. Subtypes of Barrett's oesophagus and oesophageal adenocarcinoma based on genome-wide methylation analysis.
Yu M; Maden SK; Stachler M; Kaz AM; Ayers J; Guo Y; Carter KT; Willbanks A; Heinzerling TJ; O'Leary RM; Xu X; Bass A; Chandar AK; Chak A; Elliott R; Willis JE; Markowitz SD; Grady WM
Gut; 2019 Mar; 68(3):389-399. PubMed ID: 29884612
[TBL] [Abstract][Full Text] [Related]
19. Genetic mechanisms of TP53 loss of heterozygosity in Barrett's esophagus: implications for biomarker validation.
Wongsurawat VJ; Finley JC; Galipeau PC; Sanchez CA; Maley CC; Li X; Blount PL; Odze RD; Rabinovitch PS; Reid BJ
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):509-16. PubMed ID: 16537709
[TBL] [Abstract][Full Text] [Related]
20. Effect of Barrett's esophagus surveillance on esophageal preservation, tumor stage, and survival with esophageal adenocarcinoma.
Grant KS; DeMeester SR; Kreger V; Oh D; Hagen JA; Chandrasoma P; DeMeester TR
J Thorac Cardiovasc Surg; 2013 Jul; 146(1):31-7. PubMed ID: 23312980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
